의약품 시장 : 시장 인사이트, 경쟁 구도, 시장 예측(2034년)

Pharmaceuticals Market Summary

• The global pharmaceuticals market is expected to increase from USD 1,558.67 billion in 2025 to USD 2,767.06 billion by 2034, reflecting strong and sustained growth.
• The global pharmaceuticals market is growing at a CAGR of 6.66% during the forecast period from 2026 to 2034.
• The growth of the pharmaceutical market is primarily driven by the rising demand for medications due to the increasing prevalence of various acute and chronic diseases, including cancer, cardiovascular disorders, neurological conditions, and diabetes. There is also a growing demand for biologic drugs, such as monoclonal antibodies, which offer targeted and effective treatment options. Additionally, increased investments and continuous innovations in pharmaceutical research and development are further propelling market expansion. Moreover, the surge in drug development activities among biotech companies and pharmaceutical firms is contributing significantly to this growth. Together, these trends are creating a favorable environment for sustained growth, positioning the pharmaceutical market for robust and consistent expansion throughout the forecast period from 2026 to 2034.
• The leading companies operating in the pharmaceuticals market include Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie, Inc., Sanofi, AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, GSK plc, Eli Lilly and Company, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Bayer AG, Regeneron Pharmaceutical Inc., Astellas Pharma Inc., Moderna, Inc., Biogen Inc., CSL Limited (CSL Behring), Ipsen Pharma, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Daiichi Sankyo Company, Limited, Otsuka Pharmaceutical Co., Ltd., EEisai Co., Ltd., and others.
• North America is expected to dominate the pharmaceuticals market due to its well-established healthcare infrastructure, high healthcare expenditure, and strong presence of leading pharmaceutical companies and research institutions. The region also benefits from rapid adoption of advanced drug development technologies, favorable regulatory frameworks that support innovation, and a high prevalence of chronic and lifestyle-related diseases, driving continuous drug demand. In addition, strong investment in R&D and a robust pipeline of novel therapies further strengthen North America's leadership in the global pharmaceuticals market.
• In the modality type segment of the pharmaceuticals market, the biologics category is estimated to account for the largest market share in 2025.

Factors Contributing to the Growth of the Pharmaceuticals Market

• Rising demand for pharmaceuticals owing to an increase in various acute & chronic diseases: The rising prevalence of acute and chronic diseases such as cancer, diabetes, cardiovascular disorders, respiratory infections, and neurological conditions is significantly driving the demand for pharmaceuticals. As the global patient population continues to grow due to aging demographics, lifestyle changes, and environmental factors, the need for effective and long-term treatment options is increasing. This consistent disease burden ensures sustained consumption of medicines across therapeutic areas, thereby boosting overall pharmaceutical market growth.
• Rising demand for biologic therapies: The increasing shift toward biologic therapies is positively transforming the pharmaceuticals market, as these treatments offer higher specificity, improved efficacy, and better outcomes for complex diseases. Biologics such as monoclonal antibodies, vaccines, and nucleic acid-based therapies are becoming essential in treating cancer, autoimmune disorders, and rare diseases where conventional drugs are less effective. Growing regulatory approvals and expanding clinical applications are further accelerating their adoption, contributing significantly to market expansion.
• Increasing investments and innovations in the research and development of pharmaceuticals: Rising investments in pharmaceutical R&D are driving innovation and enabling the development of advanced therapies with improved safety and efficacy profiles. Pharmaceutical companies are increasingly allocating large budgets toward drug discovery, clinical trials, and the adoption of technologies such as AI, high-throughput screening, and precision medicine. These innovations are shortening development timelines and improving success rates, thereby strengthening the drug pipeline and fueling long-term market growth.
• A growing number of drug development activities among biotech companies and pharmaceutical firms: The continuous rise in drug development activities among biotech and pharmaceutical companies is expanding the overall pharmaceutical pipeline. Companies are actively focusing on novel drug candidates, combination therapies, and next-generation biologics to address unmet medical needs. Strategic collaborations, licensing agreements, and mergers are further accelerating development processes. This strong pipeline activity ensures a steady flow of new product launches, supporting sustained market expansion.

Pharmaceuticals Market Report Segmentation

This pharmaceuticals market report offers a comprehensive overview of the global pharmaceuticals market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Modality Type (Small Molecule and Biologics [Monoclonal Antibodies, Antibody Drug Conjugates, Peptide Drug Conjugates, Nucleic Acid Medicines, Vaccines, and Others]), Product Type (Branded and Generic), Drug Type (Prescription Drugs and Over-the-Counter (OTC) Drugs), Formulation (Solid Dosage Forms, Semi-solid Dosage Forms, and Liquid Dosage Forms), Route of Administration (Oral, Parenteral, and Others), Therapy Area (Oncology, Cardiology, Neurology, Immunology, Endocrinology, Infectious Disease, and Others), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing pharmaceuticals market.

Pharmaceuticals refer to the branch of science and industry concerned with the discovery, development, production, and marketing of drugs used for the prevention, diagnosis, treatment, and management of diseases. It includes both chemical-based small molecule drugs and complex biologic therapies such as vaccines, monoclonal antibodies, and gene-based medicines. The pharmaceutical industry plays a critical role in improving global health outcomes by providing safe, effective, and regulated medicinal products that address a wide range of acute and chronic medical conditions.

The growth of the pharmaceutical market is primarily driven by the rising demand for medications due to the increasing prevalence of various acute and chronic diseases, including cancer, cardiovascular disorders, neurological conditions, and diabetes. As populations age and lifestyle-related risk factors become more common, the global burden of disease continues to rise, creating a sustained need for effective and long-term treatment options across multiple therapeutic areas. This has significantly expanded the consumption of both branded and generic drugs worldwide.

In addition, there is a growing demand for biologic drugs, such as monoclonal antibodies, vaccines, and other advanced therapies, which provide highly targeted and more effective treatment approaches compared to traditional small molecule drugs. These biologics are increasingly being used in oncology, autoimmune diseases, and rare disorders, where conventional therapies often show limited effectiveness. Their strong clinical outcomes and continuous pipeline expansion are accelerating their adoption in global healthcare systems.

Furthermore, increased investments and continuous innovations in pharmaceutical research and development are further propelling market expansion. Companies are actively investing in advanced technologies such as artificial intelligence, precision medicine, and high-throughput screening to improve drug discovery efficiency and reduce development timelines. This innovation-driven environment is enhancing the success rate of new drug candidates and strengthening the overall product pipeline.

Moreover, the surge in drug development activities among biotech companies and pharmaceutical firms is contributing significantly to this growth. Strategic collaborations, mergers, and licensing agreements are enabling faster development and commercialization of novel therapies. Together, these trends are creating a favorable environment for sustained growth, positioning the pharmaceutical market for robust and consistent expansion throughout the forecast period from 2026 to 2034.

What are the latest pharmaceutical market dynamics and trends?

The growth of the pharmaceutical market is primarily driven by the rising demand for medications due to the increasing prevalence of various acute and chronic diseases, including cancer, cardiovascular disorders, neurological conditions, and diabetes. According to GLOBOCAN (2026), the estimated new cases of cancer would rise to 32.6 million by 2045. Rising cancer cases increase demand for innovative oncology drugs, driving pharmaceutical market growth. For example, the success of immunotherapies like Merck's Keytruda, which targets multiple cancer types, has significantly boosted sales and spurred further R&D investment in cancer treatments. Additionally, the recent approvals in oncology are further escalating the market adoption and thereby boosting the market of pharmaceuticals. For instance, in May 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer.

Additionally, according to data published by the British Heart Foundation (2024), approximately 640 million people globally were affected by heart and circulatory diseases, with these numbers anticipated to rise in the coming years. The same source notes that around 67 million individuals were diagnosed with heart or circulatory diseases each year. The growing prevalence of cardiovascular diseases fuels demand for effective medications, expanding the pharmaceutical market. For instance, Pfizer's cholesterol-lowering drug, Lipitor, and newer anticoagulants like Eliquis from Bristol-Myers Squibb have seen strong sales due to increased patient needs worldwide. Additionally, in March 2024, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight.

Similarly, the global diabetes burden is rising rapidly. The International Diabetes Federation reported in 2025 that 590 million adults aged 20-79 were living with diabetes, and a number expected to increase to 853 million by 2050. Rising diabetes cases boost demand for advanced treatments, propelling pharmaceutical market growth. For example, Novo Nordisk's GLP-1 agonists like Ozempic and Wegovy have rapidly gained popularity, driving strong sales and innovation in diabetes care. Additionally, FDA-approved diabetes drugs, Awiqli (insulin icodec), were approved in March 2026.

Accoridng to the data provided by the World Health Organization (2025), neurological conditions are the leading cause of ill health and disability, affecting over 1 in 3 people worldwide. The rising prevalence of neurological disorders, including Alzheimer's Disease, Parkinson's Disease, stroke, and spinal cord injuries, is driving demand for pharmaceuticals.

Additionally, according to the World Health Organization (2024), globally, an estimated 5 million people are diagnosed with epilepsy each year. Similarly, depression remains a major global health concern. As per the WHO (2023), in 2023, an estimated 280 million people worldwide were living with depression. Increasing neurological disease cases, such as Alzheimer's disease and Parkinson's disease, drive demand for specialized therapies, expanding the pharma market. For example, Biogen's Aduhelm, targeting Alzheimer's, represents a breakthrough in treatment, stimulating further research and investment in neurological drugs.

Furthermore, the surge in R&D investment is further supported by government initiatives aimed at fostering industry-led research. For example, in August 2024, the UK government allocated EUR 12 million from the Innovate UK Cancer Therapeutics Programme to support the development of life-changing cancer treatments, including therapies for childhood and young adult cancers. Such public and private sector investments are fueling the development of new treatments and technologies, thereby propelling the market growth.

In parallel, major industry players are increasingly focusing on strategic collaborations and partnerships to accelerate drug development. For example, in June 2025, AstraZeneca announced a strategic research collaboration with China-based CSPC Pharmaceutical Group. This partnership aims to leverage AI-driven drug discovery to identify novel oral drug candidates targeting high-priority diseases across multiple therapeutic areas.

Furthermore, regulatory approvals of innovative treatments are also driving market growth. In July 2025, PTC Therapeutics, Inc. received U.S. FDA approval for SEPHIENCE(TM) (sepiapterin) for the treatment of phenylketonuria (PKU) in both adults and children as young as one month old. The drug has been approved for the treatment of hyperphenylalaninemia (HPA) in patients responsive to sepiapterin, offering a new oral treatment option for this rare metabolic disorder.

However, the stringent guidelines by regulatory bodies and governments and extensive time required for drug development in clinical trials, among others, are some of the key constraints that may limit the growth of the pharmaceutical market.

Pharmaceuticals Market Segment Analysis

Pharmaceuticals Market by Modality Type (Small Molecule and Biologics [Monoclonal Antibodies, Antibody Drug Conjugates, Peptide Drug Conjugates, Nucleic Acid Medicines, Vaccines, and Others]), Product Type (Branded and Generic), Drug Type (Prescription Drugs and Over-the-Counter (OTC) Drugs), Formulation (Solid Dosage Forms, Semi-solid Dosage Forms, and Liquid Dosage Forms), Route of Administration (Oral, Parenteral, and Others), Therapy Area (Oncology, Cardiology, Neurology, Immunology, Endocrinology, Infectious Disease, and Others), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Pharmaceuticals Market Regional Analysis

North America Pharmaceuticals Market Trends

North America is expected to account for the highest proportion of 42% of the pharmaceutical market in 2025, out of all regions. The region's leadership can be attributed to the rising demand for pharmaceutical products, fueled by the increasing prevalence of acute and chronic diseases. Additionally, significant investments in research and development, along with a high volume of clinical trials, are accelerating innovation and therapeutic advancements. The growing trend of strategic research collaborations and partnerships among pharmaceutical companies is further enhancing drug development capabilities. Together, these factors are fostering a robust and dynamic pharmaceutical ecosystem, positioning North America as a leading contributor to global market growth.

As per the data from GLOBOCAN (2026), the estimated new cases of cancer would rise to 3.83 million by 2045 in North America. Additionally, according to the American Heart Association (2024), approximately 9.7 million adults were living with undiagnosed diabetes, while 29.3 million have been diagnosed. According to an article published by the Centers for Disease Control and Prevention (2024), approximately 6.2 million adults were suffering from heart failure in the United States. The rising cases of acute and chronic diseases like cancer, diabetes, and heart conditions are increasing demand for effective and long-term treatments, fueling pharmaceutical market growth. For example, the global surge in diabetes has driven strong sales of Novo Nordisk's GLP-1 drugs like Ozempic and Wegovy.

Additionally, rising investment in biopharmaceuticals is accelerating innovation and expanding the global pharmaceutical market. For instance, in July 2025, AstraZeneca announced a $50 billion U.S. investment through 2030, including new manufacturing and R&D facilities, aiming to bolster its oncology and cardiovascular drug pipelines, targeting $80 billion in annual revenue by 2030. Similarly, India's biopharma sector is projected to reach $63 billion by 2025, driven by advancements in biosimilars, biologics, and vaccines.

The global rise in clinical trial activity further reinforces this trend. ClinicalTrials.gov reported that by 2024, over 518,210 clinical trials were registered, up from 477,219 in 2023, highlighting the surge in drug development initiatives. Such a rising number of trials is further propelling the market expansion in the region.

Moreover, key industry players are actively launching new products across various therapeutic areas, further accelerating market growth in the North American region. For instance, in July 2025, LEO Pharma, a global leader in medical dermatology, received U.S. FDA approval for ANZUPGO(R) (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults. Similarly, in the same month, KalVista Pharmaceutical announced the FDA approval of EKTERLY(R) (sebetralstat), the first and only oral, on-demand treatment for hereditary angioedema (HAE). Such product approvals and launches not only address unmet medical needs but also significantly contribute to the expanding pharmaceutical landscape in North America, reinforcing its position as a market leader.

In summary, the growing incidence of chronic and infectious diseases, combined with rapid technological innovation, is positioning North America as a leader in the harmaceuticals market.

Europe Pharmaceuticals Market Trend

The European pharmaceutical market is witnessing strong and sustained growth due to a combination of powerful structural drivers such as rising healthcare expenditure, an aging population, increasing prevalence of chronic diseases, and continuous innovation in drug development, particularly in oncology and biologics. The region is also benefiting from strong regulatory oversight by the European Medicines Agency (EMA), which ensures faster approval of high-quality innovative medicines and supports market entry of new therapies, including biologics and biosimilars. In addition, recent policy reforms such as the EU pharmaceutical package (2025) are aimed at accelerating patient access and strengthening competitiveness, further supporting market expansion.

Recent approvals and launches are also reinforcing this growth momentum. For example, Givinostat (Duvyzat) was authorized in the European Union in June 2025 for the treatment of Duchenne muscular dystrophy, marking an important advancement in rare disease therapy. Similarly, biosimilar medicines such as Gotenfia, approved in the EU in February 2026, are expanding affordable treatment access and increasing market penetration of biologic alternatives. Additionally, other innovative therapies like Wainua (eplontersen) received EU marketing authorization in March 2025, reflecting Europe's strong pipeline of novel drug approvals.

Furthermore, in January 2025, the European Medicines Agency (EMA) recommended approval of Datroway (datopotamab deruxtecan) for the treatment of certain patients with breast cancer. In January 2025, EMA recommended approval of Tivdak (tisotumab vedotin) for the treatment of recurrent or metastatic cervical cancer. Furthermore, in February 2025, EMA recommended approval of Lynozyfic (linvoseltamab) for patients with relapsed or refractory multiple myeloma.

Together, these factors, rising disease burden, strong regulatory support, increasing biologics adoption, and continuous product approvals, are creating a highly favorable environment for sustained growth of the pharmaceutical market in Europe.

Asia-Pacific Pharmaceuticals Market Trends

The Asia Pacific (APAC) region is emerging as a major growth driver for the pharmaceuticals market due to its large and rapidly growing population, increasing prevalence of chronic and infectious diseases, and expanding access to healthcare services. Rising healthcare expenditure, improving medical infrastructure, and strong government initiatives to enhance drug accessibility are further supporting market expansion. In addition, the region is witnessing significant growth in pharmaceutical manufacturing, clinical research activities, and the presence of cost-effective production hubs in countries like China and India. Growing adoption of generics and biosimilars, along with increasing investments from global pharmaceutical companies, is further accelerating the region's pharmaceutical market growth.

Who are the major players in the pharmaceuticals market?

The following are the leading companies in the pharmaceuticals market. These companies collectively hold the largest market share and dictate industry trends.

• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• AbbVie, Inc.
• Sanofi
• AstraZeneca
• Novartis AG
• Bristol-Myers Squibb Company
• GSK plc
• Eli Lilly and Company
• Gilead Sciences, Inc.
• Takeda Pharmaceutical Company Limited
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Bayer AG
• Regeneron Pharmaceutical Inc.
• Astellas Pharma Inc.
• Moderna, Inc.
• Biogen Inc.
• CSL Limited (CSL Behring)
• Ipsen Pharma
• Alnylam Pharmaceuticals, Inc.
• Vertex Pharmaceuticals Incorporated
• Jazz Pharmaceuticals plc
• Daiichi Sankyo Company, Limited
• Otsuka Pharmaceutical Co., Ltd.,
• Eisai Co., Ltd.
• Others

How is the competitive landscape shaping the pharmaceuticals market?

The competitive landscape of the pharmaceuticals market is highly dynamic and is being shaped by intense innovation, strategic collaborations, and increasing consolidation among key players. Leading pharmaceutical companies are heavily investing in research and development to build strong drug pipelines, particularly in high-growth areas such as oncology, immunology, rare diseases, and biologics. At the same time, mergers, acquisitions, and licensing agreements are becoming common strategies to expand therapeutic portfolios and accelerate time-to-market for new drugs. The rise of biosimilars and generics is also intensifying price competition, especially after patent expiries of blockbuster drugs, pushing companies to focus on cost efficiency and differentiated therapies. Additionally, emerging biotech firms are playing a crucial role by introducing innovative technologies such as gene therapy, cell therapy, and AI-driven drug discovery, further increasing competition and reshaping the global pharmaceutical industry landscape.

Recent Developmental Activities in the Pharmaceuticals Market

• In July 2025, PTC Therapeutics, Inc. received U.S. FDA approval for SEPHIENCE(TM) (sepiapterin) for the treatment of phenylketonuria (PKU) in both adults and children as young as one month old. The drug has been approved for the treatment of hyperphenylalaninemia (HPA) in patients responsive to sepiapterin, offering a new oral treatment option for this rare metabolic disorder.
• In July 2025, LEO Pharma, a global leader in medical dermatology, received U.S. FDA approval for ANZUPGO(R) (delgocitinib) cream (20 mg/g) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults.

Pharmaceuticals Market Segmentation

• Pharmaceuticals by Modality Type Exposure
• Small Molecule
• Biologics
• Monoclonal Antibodies
• Antibody Drug Conjugates
• Peptide Drug Conjugates
• Nucleic Acid Medicines
• Vaccines
• Others
• Pharmaceuticals by Product Type Exposure
• Branded
• Generic
• Pharmaceuticals Drug Type Exposure
• Prescription Drugs
• Over-the-Counter (OTC) Drugs
• Pharmaceuticals Formulation Exposure
• Solid Dosage Forms
• Semi-solid Dosage Forms
• Liquid Dosage Forms
• Pharmaceuticals Route of Administration Exposure
• Oral
• Parenteral
• Others
• Pharmaceuticals Therapy Area Exposure
• Oncology
• Cardiology
• Neurology
• Immunology
• Endocrinology
• Infectious Disease
• Others
• Pharmaceuticals Distribution Channel Exposure
• Hospital & Retail Pharmacies
• Online Pharmacies
• Pharmaceuticals Geography Exposure
• North America Pharmaceuticals Market
• United States Pharmaceuticals Market
• Canada Pharmaceuticals Market
• Mexico Pharmaceuticals Market
• Europe Pharmaceuticals Market
• United Kingdom Pharmaceuticals Market
• Germany Pharmaceuticals Market
• France Pharmaceuticals Market
• Italy Pharmaceuticals Market
• Spain Pharmaceuticals Market
• Rest of Europe Pharmaceuticals Market
• Asia-Pacific Pharmaceuticals Market
• China Pharmaceuticals Market
• Japan Pharmaceuticals Market
• India Pharmaceuticals Market
• Australia Pharmaceuticals Market
• South Korea Pharmaceuticals Market
• Rest of Asia-Pacific Pharmaceuticals Market
• Rest of the World Pharmaceuticals Market
• South America Pharmaceuticals Market
• Middle East Pharmaceuticals Market
• Africa Pharmaceuticals Market

Key takeaways from the pharmaceuticals market report study

• Market size analysis for the current pharmaceuticals market size (2025), and market forecast for 8 years (2026 to 2034)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the pharmaceuticals market.
• Various opportunities available for the other competitors in the pharmaceuticals market space.
• What are the top-performing segments in 2025? How these segments will perform in 2034?
• Which are the top-performing regions and countries in the current pharmaceuticals market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the pharmaceutical market growth in the future.

Frequently Asked Questions for the Pharmaceuticals Market

1. What is the growth rate of the pharmaceuticals market?

• The pharmaceuticals market is estimated to grow at a CAGR of 6.66% during the forecast period from 2026 to 2034.

2. What is the market for pharmaceuticals?

• The global pharmaceuticals market is expected to increase from USD 1,558.67 billion in 2025 to USD 2,767.06 billion by 2034.

3. Which region has the highest share in the pharmaceuticals market?

• North America is expected to dominate the pharmaceuticals market due to its well-established healthcare infrastructure, high healthcare expenditure, and strong presence of leading pharmaceutical companies and research institutions. The region also benefits from rapid adoption of advanced drug development technologies, favorable regulatory frameworks that support innovation, and a high prevalence of chronic and lifestyle-related diseases, driving continuous drug demand. In addition, strong investment in R&D and a robust pipeline of novel therapies further strengthen North America's leadership in the global pharmaceuticals market.

4. What are the drivers for the pharmaceuticals market?

• The growth of the pharmaceutical market is primarily driven by the rising demand for medications due to the increasing prevalence of various acute and chronic diseases, including cancer, cardiovascular disorders, neurological conditions, and diabetes. There is also a growing demand for biologic drugs, such as monoclonal antibodies, which offer targeted and effective treatment options. Additionally, increased investments and continuous innovations in pharmaceutical research and development are further propelling market expansion. Moreover, the surge in drug development activities among biotech companies and pharmaceutical firms is contributing significantly to this growth. Together, these trends are creating a favorable environment for sustained growth, positioning the pharmaceutical market for robust and consistent expansion throughout the forecast period from 2026 to 2034.

5. Who are the key players operating in the pharmaceuticals market?

• Some of the key market players operating in the pharmaceuticals market include Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie, Inc., Sanofi, AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, GSK plc, Eli Lilly and Company, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Bayer AG, Regeneron Pharmaceutical Inc., Astellas Pharma Inc., Moderna, Inc., Biogen Inc., CSL Limited (CSL Behring), Ipsen Pharma, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Daiichi Sankyo Company, Limited, Otsuka Pharmaceutical Co., Ltd., EEisai Co., Ltd., and others.

Table of Contents

1. Pharmaceuticals Market Report Introduction

• 1.1 Scope of the Study
• 1.2 Market Segmentation
• 1.3 Market Assumption

2. Pharmaceuticals Market Executive Summary

• 2.1 Market at Glance

3. Pharmaceuticals Market Key Factors Analysis

• 3.1 Pharmaceuticals Market Drivers
  • 3.1.1 Rising demand for pharmaceuticals owing to an increase in various acute & chronic diseases
  • 3.1.2 Rising demand for biologic therapies
  • 3.1.3 Increasing investments and innovations in the research and development of pharmaceutical
  • 3.1.4 A growing number of drug development activities among biotech companies and pharmaceutical firms
• 3.2 Pharmaceuticals Market Restraints and Challenges
  • 3.2.1 Stringent guidelines by regulatory bodies and governments
  • 3.2.2 Extensive time is required for drug development in clinical trials
• 3.3 Pharmaceuticals Market Opportunity
  • 3.3.1 The shift toward precision medicine and targeted therapies
  • 3.3.2 Presence of an extensive drug portfolio in the pipeline for various indications

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

• 5.1 The United States
• 5.2 Europe
• 5.3 Japan
• 5.4 China

6. Pharmaceuticals Market Porter's Five Forces Analysis

• 6.1 Bargaining Power of Suppliers
• 6.2 Bargaining Power of Consumers
• 6.3 Threat of New Entrants
• 6.4 Threat of Substitutes
• 6.5 Competitive Rivalry

7. Pharmaceuticals Market Assessment

• 7.1 By Modality Type
  • 7.1.1 Small Molecule
  • 7.1.2 Biologics
    • 7.1.2.1 Monoclonal Antibodies
    • 7.1.2.2 Antibody Drug Conjugates
    • 7.1.2.3 Peptide Drug Conjugates
    • 7.1.2.4 Nucleic Acid Medicines
    • 7.1.2.5 Vaccines
    • 7.1.2.6 Others
• 7.2 By Product Type
  • 7.2.1 Branded
  • 7.2.2 Generic
• 7.3 By Drug Type
  • 7.3.1 Prescription Drugs
  • 7.3.2 Over-the-Counter (OTC) Drugs
• 7.4 By Formulation
  • 7.4.1 Solid Dosage Forms
  • 7.4.2 Semi-solid Dosage Forms
  • 7.4.3 Liquid Dosage Forms
• 7.5 By Route of Administration
  • 7.5.1 Solid Dosage Forms
  • 7.5.2 Semi-solid Dosage Forms
  • 7.5.3 Liquid Dosage Forms
• 7.6 By Therapy Area
  • 7.6.1 Oncology
  • 7.6.2 Cardiology
  • 7.6.3 Neurology
  • 7.6.4 Immunology
  • 7.6.5 Endocrinology
  • 7.6.6 Infectious Disease
  • 7.6.7 Others
• 7.7 By Distribution Channel
  • 7.7.1 Hospital & Retail Pharmacies
  • 7.7.2 Online Pharmacies
• 7.8 By Geography
  • 7.8.1 North America
    • 7.8.1.1 United States Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.1.2 Canada Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.1.3 Mexico Pharmaceuticals Market Size in USD million (2023-2034)
  • 7.8.2 Europe
    • 7.8.2.1 France Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.2.2 Germany Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.2.3 United Kingdom Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.2.4 Italy Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.2.5 Spain Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.2.6 Rest of Europe Pharmaceuticals Market Size in USD million (2023-2034)
  • 7.8.3 Asia-Pacific
    • 7.8.3.1 China Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.3.2 Japan Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.3.3 India Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.3.4 Australia Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.3.5 South Korea Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.3.6 Rest of Asia-Pacific Pharmaceuticals Market Size in USD million (2023-2034)
  • 7.8.4 Rest of the World (RoW)
    • 7.8.4.1 Middle East Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.4.2 Africa Pharmaceuticals Market Size in USD million (2023-2034)
    • 7.8.4.3 South America Pharmaceuticals Market Size In USD Million (2023-2034)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Pharmaceuticals Market Company and Product Profiles

• 10.1 Pfizer Inc.
  • 10.1.1 Company Overview
  • 10.1.2 Company Snapshot
  • 10.1.3 Financial Overview
  • 10.1.4 Product Listing
  • 10.1.5 Entropy
• 10.2 Johnson & Johnson Services, Inc.
  • 10.2.1 Company Overview
  • 10.2.2 Company Snapshot
  • 10.2.3 Financial Overview
  • 10.2.4 Product Listing
  • 10.2.5 Entropy
• 10.3 F. Hoffmann-La Roche Ltd.
  • 10.3.1 Company Overview
  • 10.3.2 Company Snapshot
  • 10.3.3 Financial Overview
  • 10.3.4 Product Listing
  • 10.3.5 Entropy
• 10.4 Merck & Co., Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Snapshot
  • 10.4.3 Financial Overview
  • 10.4.4 Product Listing
  • 10.4.5 Entropy
• 10.5 AbbVie, Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Company Snapshot
  • 10.5.3 Financial Overview
  • 10.5.4 Product Listing
  • 10.5.5 Entropy
• 10.6 Sanofi
  • 10.6.1 Company Overview
  • 10.6.2 Company Snapshot
  • 10.6.3 Financial Overview
  • 10.6.4 Product Listing
  • 10.6.5 Entropy
• 10.7 AstraZeneca
  • 10.7.1 Company Overview
  • 10.7.2 Company Snapshot
  • 10.7.3 Financial Overview
  • 10.7.4 Product Listing
  • 10.7.5 Entropy
• 10.8 Novartis AG
  • 10.8.1 Company Overview
  • 10.8.2 Company Snapshot
  • 10.8.3 Financial Overview
  • 10.8.4 Product Listing
  • 10.8.5 Entropy
• 10.9 Bristol-Myers Squibb Company
  • 10.9.1 Company Overview
  • 10.9.2 Company Snapshot
  • 10.9.3 Financial Overview
  • 10.9.4 Product Listing
  • 10.9.5 Entropy
• 10.10 GSK plc.
  • 10.10.1 Company Overview
  • 10.10.2 Company Snapshot
  • 10.10.3 Financial Overview
  • 10.10.4 Product Listing
  • 10.10.5 Entropy
• 10.11 Eli Lilly and Company
  • 10.11.1 Company Overview
  • 10.11.2 Company Snapshot
  • 10.11.3 Financial Overview
  • 10.11.4 Product Listing
  • 10.11.5 Entropy
• 10.12 Gilead Sciences, Inc.
  • 10.12.1 Company Overview
  • 10.12.2 Company Snapshot
  • 10.12.3 Financial Overview
  • 10.12.4 Product Listing
  • 10.12.5 Entropy
• 10.13 Takeda Pharmaceutical Company Limited
  • 10.13.1 Company Overview
  • 10.13.2 Company Snapshot
  • 10.13.3 Financial Overview
  • 10.13.4 Product Listing
  • 10.13.5 Entropy
• 10.14 Novo Nordisk A/S
  • 10.14.1 Company Overview
  • 10.14.2 Company Snapshot
  • 10.14.3 Financial Overview
  • 10.14.4 Product Listing
  • 10.14.5 Entropy
• 10.15 Teva Pharmaceutical Industries Ltd.
  • 10.15.1 Company Overview
  • 10.15.2 Company Snapshot
  • 10.15.3 Financial Overview
  • 10.15.4 Product Listing
  • 10.15.5 Entropy
• 10.16 Amgen Inc.
  • 10.16.1 Company Overview
  • 10.16.2 Company Snapshot
  • 10.16.3 Financial Overview
  • 10.16.4 Product Listing
  • 10.16.5 Entropy
• 10.17 Boehringer Ingelheim International GmbH
  • 10.17.1 Company Overview
  • 10.17.2 Company Snapshot
  • 10.17.3 Financial Overview
  • 10.17.4 Product Listing
  • 10.17.5 Entropy
• 10.18 Viatris Inc.
  • 10.18.1 Company Overview
  • 10.18.2 Company Snapshot
  • 10.18.3 Financial Overview
  • 10.18.4 Product Listing
  • 10.18.5 Entropy
• 10.19 Bayer AG
  • 10.19.1 Company Overview
  • 10.19.2 Company Snapshot
  • 10.19.3 Financial Overview
  • 10.19.4 Product Listing
  • 10.19.5 Entropy
• 10.20 Regeneron Pharmaceutical Inc.
  • 10.20.1 Company Overview
  • 10.20.2 Company Snapshot
  • 10.20.3 Financial Overview
  • 10.20.4 Product Listing
  • 10.20.5 Entropy
• 10.21 Astellas Pharma Inc.
  • 10.21.1 Company Overview
  • 10.21.2 Company Snapshot
  • 10.21.3 Financial Overview
  • 10.21.4 Product Listing
  • 10.21.5 Entropy
• 10.22 Moderna, Inc.
  • 10.22.1 Company Overview
  • 10.22.2 Company Snapshot
  • 10.22.3 Financial Overview
  • 10.22.4 Product Listing
  • 10.22.5 Entropy
• 10.23 Biogen Inc.
  • 10.23.1 Company Overview
  • 10.23.2 Company Snapshot
  • 10.23.3 Financial Overview
  • 10.23.4 Product Listing
  • 10.23.5 Entropy
• 10.24 CSL Limited (CSL Behring)
  • 10.24.1 Company Overview
  • 10.24.2 Company Snapshot
  • 10.24.3 Financial Overview
  • 10.24.4 Product Listing
  • 10.24.5 Entropy
• 10.25 Ipsen Pharma
  • 10.25.1 Company Overview
  • 10.25.2 Company Snapshot
  • 10.25.3 Financial Overview
  • 10.25.4 Product Listing
  • 10.25.5 Entropy
• 10.26 Alnylam Pharmaceuticals, Inc.
  • 10.26.1 Company Overview
  • 10.26.2 Company Snapshot
  • 10.26.3 Financial Overview
  • 10.26.4 Product Listing
  • 10.26.5 Entropy
• 10.27 Vertex Pharmaceuticals Incorporated
  • 10.27.1 Company Overview
  • 10.27.2 Company Snapshot
  • 10.27.3 Financial Overview
  • 10.27.4 Product Listing
  • 10.27.5 Entropy
• 10.28 Jazz Pharmaceuticals plc.
  • 10.28.1 Company Overview
  • 10.28.2 Company Snapshot
  • 10.28.3 Financial Overview
  • 10.28.4 Product Listing
  • 10.28.5 Entropy
• 10.29 Daiichi Sankyo Company, Limited
  • 10.29.1 Company Overview
  • 10.29.2 Company Snapshot
  • 10.29.3 Financial Overview
  • 10.29.4 Product Listing
  • 10.29.5 Entropy
• 10.30 Otsuka Pharmaceutical Co., Ltd.
  • 10.30.1 Company Overview
  • 10.30.2 Company Snapshot
  • 10.30.3 Financial Overview
  • 10.30.4 Product Listing
  • 10.30.5 Entropy
• 10.31 EEisai Co., Ltd.
  • 10.31.1 Company Overview
  • 10.31.2 Company Snapshot
  • 10.31.3 Financial Overview
  • 10.31.4 Product Listing
  • 10.31.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us